Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · Real-Time Price · USD
2.360
+0.010 (0.43%)
At close: Mar 28, 2025, 4:00 PM
2.340
-0.020 (-0.84%)
After-hours: Mar 28, 2025, 7:56 PM EDT
MRVI Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for MRVI stock have an average target of 7.59, with a low estimate of 2.50 and a high estimate of 15. The average target predicts an increase of 221.61% from the current stock price of 2.36.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for MRVI stock from 10 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 1 | 2 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 3 | 5 | 4 | 4 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Total | 9 | 11 | 11 | 11 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $7 → $5 | Hold | Maintains | $7 → $5 | +111.86% | Mar 25, 2025 |
| UBS | UBS | Hold Maintains $8 → $2.5 | Hold | Maintains | $8 → $2.5 | +5.93% | Mar 21, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +238.98% | Mar 3, 2025 |
| Baird | Baird | Buy → Hold Downgrades $9 → $3 | Buy → Hold | Downgrades | $9 → $3 | +27.12% | Feb 26, 2025 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Sell Downgrades $7 → $4.25 | Hold → Strong Sell | Downgrades | $7 → $4.25 | +80.08% | Dec 5, 2024 |
Financial Forecast
Revenue This Year
269.04M
from 259.19M
Increased by 3.80%
Revenue Next Year
299.04M
from 269.04M
Increased by 11.15%
EPS This Year
-0.07
from -1.05
EPS Next Year
0.00
from -0.07
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 296.2M | 339.8M | 359.3M | ||
| Avg | 269.0M | 299.0M | 339.5M | ||
| Low | 229.7M | 253.5M | 317.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.3% | 26.3% | 20.2% | ||
| Avg | 3.8% | 11.2% | 13.5% | ||
| Low | -11.4% | -5.8% | 6.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.01 | 0.11 | 0.14 | ||
| Avg | -0.07 | 0.00 | 0.02 | ||
| Low | -0.20 | -0.15 | -0.09 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 74,246.4% | ||
| Avg | - | - | 11,011.1% | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.